Stephane Borentain, MD

Effect of Benzodiazepines on Esketamine Nasal Spray for Treating Patients With Major Depressive Disorder With Active Suicidal Ideation and Intent

Aim: To examine potential effects of concomitant benzodiazepines on the safety and efficacy of esketamine nasal spray following first-dose treatment of patients in urgent need of symptom ...

Dong Jing Fu , MD, PhD;

Bettina Diekamp , PhD;

Janssen Cilag ;

Stephane Borentain , MD;

Robert Murray , MSc, MPH;

Kristin Heerlein , MD;

Qiaoyi Zhang , MD, PhD;

Cornelius S. , MD;

Maju Mathews , MD;

10/08/2020

Impact of Individual and Class of Concomitant Oral Antidepressant on the Efficacy and Safety of Esketamine Nasal Spray in Patients With Treatment Resistant Depression

Objective: Phase 3 trials have demonstrated the efficacy and safety of esketamine nasal spray (ESK) plus a newly initiated oral antidepressant (AD) for treatment-resistant depression (TRD...

Ibrahim Turkoz , PhD;

Jennifer Kern Sliwa , PharmD, BCPP;

Ella Daly , MB, BCh, BAO;

Jaskaran Singh , MD;

Stephane Borentain , MD;

Muideen Adigun , PharmD;

11/22/2019

Impact of Treatment With Esketamine Nasal Spray in Patients With Treatment Resistant Depression and Comorbid Anxiety: A Post-hoc Pooled Analysis of the TRANSFORM 1 and 2 Trials

Purpose: To evaluate the impact of esketamine (ESK) nasal spray in patients with treatment-resistant depression (TRD) and comorbid anxiety.

Ibrahim Turkoz , PhD;

Ella Daly , MB, BCh, BAO;

Stephane Borentain , MD;